Nivolumab companion diagnostic - Biodesix

Drug Profile

Nivolumab companion diagnostic - Biodesix

Alternative Names: BDX 008

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biodesix
  • Class Diagnostic agents; Protein diagnostics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 25 Oct 2017 Clinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route) before October 2017
  • 13 Nov 2015 Efficacy data from a clinical trial in Malignant melanoma released by Biodesix
  • 03 Nov 2015 Clinical trials in Malignant melanoma (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top